Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Unicycive Secures Patent for Kidney Disease Treatment UNI-494, Valid Until 2040
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the issuance of U.S. Patent No. 12,036,211 by the United States Patent and Trademark Office (USPTO) for UNI-494.
臨床階段的生物技術公司Unicycive Therapeutics, Inc. (NASDAQ: UNCY)開發針對腎病患者的治療方案（公司簡稱“公司”或“Unicycive”），今天宣佈美國專利和商標局（USPTO）頒發了U.S.專利號12,036,211，涉及UNI-494。
The patent, valid until 2040, secures protection of a method of treating a disease or a condition selected from acute kidney injury or contrast induced nephropathy by administering the UNI-494 compound. The UNI-494 compound covered in the method of use claims is not limited to a particular salt, dose or type of administration. UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease.
有效期至2040年的專利，確保通過注射UNI-494化合物治療急性腎損傷或造影劑腎病的方法受到保護。使用權索賠方面涉及的UNI-494化合物不侷限於特定的鹽、劑量或類型。UNI-494是一種新穎的煙酰胺酯衍生物，是一種選擇性的ATP敏感線粒體鉀通道激動劑。線粒體功能障礙在急性腎損傷和慢性腎病的進展過程中發揮着關鍵作用。